Decoy Therapeutics, Inc. (DCOY)
3.11
-0.09
(-2.81%)
USD |
NASDAQ |
Aug 24, 16:00
3.11
0.00 (0.00%)
After-Hours: 20:00
Decoy Therapeutics EPS Diluted (Quarterly) : -4.462 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.462 |
| March 31, 2026 | -4.182 |
| December 31, 2025 | -16.88 |
| September 30, 2025 | -21.76 |
| June 30, 2025 | -81.21 |
| March 31, 2025 | -1.027 |
| December 31, 2024 | -182.84 |
| September 30, 2024 | -0.7584 |
| June 30, 2024 | -2.372 |
| March 31, 2024 | -3.271 |
| December 31, 2023 | -1.791 |
| September 30, 2023 | -5.206 |
| June 30, 2023 | -11.45 |
| March 31, 2023 | -17.86 |
| December 31, 2022 | -22.62 |
| September 30, 2022 | -51.28 |
| June 30, 2022 | -17.63 |
| December 31, 2021 | -18.15 |
| September 30, 2021 | -16.68 |
| June 30, 2021 | -13.74 |
| March 31, 2021 | -12.12 |
| December 31, 2020 | -17.01 |
| September 30, 2020 | -19.11 |
| June 30, 2020 | -25.58 |
| Date | Value |
|---|---|
| March 31, 2020 | -43.71 |
| December 31, 2019 | -87.82 |
| September 30, 2019 | -145.75 |
| June 30, 2019 | -269676.0 |
| March 31, 2019 | -577286.9 |
| December 31, 2018 | -499229.9 |
| September 30, 2018 | -180738.0 |
| June 30, 2018 | -2509.20 |
| March 31, 2018 | -2297.75 |
| December 31, 2017 | -2300.00 |
| September 30, 2017 | -2700.00 |
| June 30, 2017 | -462581.9 |
| March 31, 2017 | -2450.00 |
| December 31, 2016 | -2400.00 |
| September 30, 2016 | -3250.00 |
| June 30, 2016 | -3550.00 |
| March 31, 2016 | -3050.00 |
| December 31, 2015 | -2550.00 |
| September 30, 2015 | -2650.00 |
| June 30, 2015 | -2350.00 |
| March 31, 2015 | -2950.00 |
| December 31, 2014 | -9100.00 |
| September 30, 2014 | -265.45 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Palatin Technologies, Inc. | -0.3663 |
| Unicycive Therapeutics, Inc. | -0.064 |
| Nuvectis Pharma, Inc. | -0.299 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.374M |
| Revenue (Quarterly) | 0.2276M |
| Total Expenses (Quarterly) | 2.601M |
| Enterprise Value | -6.635M |
| Gross Profit Margin (Quarterly) | 94.02% |
| Profit Margin (Quarterly) | -1.04K% |
| Earnings Yield | -1.52K% |
| Normalized Earnings Yield | -1160.02 |